ACTOVEGIN 40mg/ml, 5 ml x 5 ampoules

  • $25.70
Sku: 635b0b335563
Ingredient: Deproteinized Hemoderivative of calf blood
1 ml contains

  • Active ingredient - deproteinized hemoderivate of calf blood (in terms of dry matter) * 40.0 mg.

  • Excipient: water for injection

*contains approximately 26.8 mg sodium chloride


Pharmacological properties


It is impossible to study the pharmacokinetic characteristics (absorption, distribution, excretion) of Actovegin, since it consists only of physiological components that are usually present in the body.

Actovegin has an antihypoxic effect, which begins to manifest itself no later than 30 minutes after parenteral administration. The maximum effect is observed 3 hours after parenteral and 2-6 hours after oral administration.


Actovegin is a gemoderivate, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass). Actovegin is an antihypoxant that has three types of effects: metabolic, neuroprotective and microcirculatory. Actovegin increases the uptake and utilization of oxygen; the phospho-oligosaccharides included in the preparation inositol have a positive effect on the transport and utilization of glucose, which leads to an improvement in the energy metabolism of cells and a decrease in the formation of lactate in conditions of ischemia. The activity of Actovegin was confirmed by measuring increased absorption and increased utilization of glucose and oxygen.

Several ways of implementing the neuroprotective mechanism of drug action are considered.

Actovegin prevents the development of apoptosis induced by the beta-amyloid peptide (Aβ25-35).

Actovegin modulates the activity of nuclear factor kappa B (NF-kB), which plays an important role in the regulation of apoptosis and inflammation in the central and peripheral nervous system.

Another mechanism of action is associated with the nuclear enzyme poly (ADP-ribose) polymerase (PARP). PARP plays an important role in the detection and repair of single-stranded DNA damage, but excessive activation of the enzyme can trigger cell death in conditions such as cerebrovascular disease and diabetic polyneuropathy. Actovegin inhibits the activity of PARP, which leads to a functional and morphological improvement in the state of the central and peripheral nervous system. The positive effects of the drug Actovegin, affecting the processes of microcirculation and the endothelium, are an increase in the rate of capillary blood flow, a decrease in the pericapillary zone, a decrease in the myogenic tone of precapillary arterioles and capillary sphincters,

In the course of various studies, it was found that the effect of the drug Actovegin occurs no later than 30 minutes after its administration. The maximum effect is observed 3 hours after parenteral and 2-6 hours after oral administration.

The effect of Actovegin on oxygen uptake and utilization, as well as insulin-like activity with stimulation of glucose transport and oxidation, are significant in the treatment of diabetic polyneuropathy (DPN).

In patients with diabetes mellitus and diabetic polyneuropathy, Actovegin significantly reduces the symptoms of polyneuropathy (stabbing pain, burning sensation, paresthesia, numbness in the lower extremities). Objectively, sensitivity disorders are reduced, the mental well-being of patients improves.


Indications for use

As part of complex therapy:

- symptomatic treatment of cognitive impairment, including post-stroke cognitive impairment and dementia.

- symptomatic treatment of peripheral circulatory disorders and their consequences.

- symptomatic treatment of diabetic polyneuropathy (DPN).


Dosage and administration

Actovegin, solution for injection, is used intramuscularly, intravenously (including in the form of infusions) or intra-arterially.

Instructions for using ampoules with one break point:

take the ampoule so that the top containing the label is at the top. Gently tapping with your finger and shaking the ampoule, allow the solution to flow down from the tip of the ampoule. Break off the top of the ampoule by pressing on the mark.

Depending on the severity of the clinical picture, at first, 10-20 ml of the drug should be administered intravenously or intra-arterially daily; for further treatment, 5 ml intravenously or intramuscularly slowly, daily or several times a week. For infusion administration, from 10 to 50 ml of the drug should be added to 200-300 ml of the stock solution (isotonic sodium chloride solution or 5% glucose solution). The infusion rate is about 2 ml/min.

For intramuscular injections, no more than 5 ml of the drug is used, which should be administered slowly, since the solution is hypertonic.

Post-stroke cognitive impairment

In the acute period of ischemic stroke, starting from 5-7 days, 2000 mg per day intravenously, up to 20 infusions with the transition to a tablet form, 2 tablets 3 times a day (1200 mg / day). The total duration of treatment is 6 months.


2000 mg per day intravenously for up to 4 weeks.

Peripheral circulatory disorders and their consequences

800 - 2000 mg per day intra-arterially or intravenously drip. The duration of treatment is up to 4 weeks.

Diabetic polyneuropathy

2000 mg per day intravenously, 20 infusions with the transition to a tablet form, 3 tablets 3 times a day (1800 mg / day) for a period of 4 to 5 months.


Side effects

The frequency of side effects was determined in accordance with the classification of the Council of International Medical Scientific Organizations (CIOMS): very often (≥ 1/10); often (≥ 1/100 to <1/10); infrequently (≥ 1/1000 to <1/100); rarely (≥ 1/10000 to <1/1000); very rarely (<1/10000); unknown (cannot be estimated from the available data).

Immune System Disorders

Rare : allergic reactions (drug fever, symptoms of shock).

Skin and subcutaneous tissue disorders

Rare : urticaria, sudden redness.

Musculoskeletal and connective tissue disorders :

Not known: myalgia.



- hypersensitivity to the components of the drug Actovegin

- general contraindications to infusion therapy: decompensated heart failure, pulmonary edema, oliguria, anuria, hyperhydration

- children's age up to 18 years.


Special instructions

Parenteral administration of the drug should be carried out under sterile conditions.

Due to the possibility of an anaphylactic reaction, a test injection (hypersensitivity test) is recommended.

In the case of electrolyte disorders (such as hyperchloremia and hypernatremia), these conditions should be adjusted accordingly.

The solution for injection has a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the starting materials used, but this does not adversely affect the activity of the drug or its tolerability.

Do not use a solution that is opaque or contains particles.

After opening the ampoule, the solution cannot be stored.

Clinical Data

In the ARTEMIDA multicenter, randomized, double-blind, placebo-controlled study (NCT01582854), which aimed to study the therapeutic effect of Actovegin on cognitive impairment in 503 patients with ischemic stroke, the overall incidence of serious adverse events and death was the same in both treatment groups. Although the frequency of recurrent ischemic strokes was within the expected range in this patient population, there were more cases in the Actovegin group than in the placebo group, but this difference was not statistically significant. An association between recurrent stroke events and study drug was not established.

Use in pediatric patients

Currently, data on the use of the drug Actovegin in children are not available, so its use in this group of people is not recommended.

Influence on the ability to drive a car and other mechanisms

Not installed.

Use during pregnancy and lactation

Actovegin should only be used when the therapeutic benefit outweighs the potential risk to the fetus or child.




There is no data on the possibility of overdose with Actovegin. Based on pharmacological data, no additional undesirable effects are expected.


Storage conditions


Store in a place protected from light at a temperature not exceeding 25C.

Keep out of the reach of children!

Shelf life - 3 years

Do not use the drug after the expiration date
Write a review
Related Products
Nobel AFF (Kazakhstan)
Kloviks 14s 75 mg film-coated tablets
KRKA, d.d., Novo Mesto (Slovenia)
Ko Amlessa 4 mg / 5 mg / 1.25 mg (30 tablets)
Egis (Hungary)
Cardilopin 10 mg (30 tablets)
KRKA, d.d., Novo Mesto (Slovenia)
Ko Amlessa 8 mg / 10 mg / 2.5 mg (30 tablets)
KRKA (Slovenia)
Atoris 30s 10 mg coated tablets
Kleva SA (Greece)
Toksivenol 300 mg / 3 30s mg coated tablets
KhimPharm (Kazakhstan)
Kvoreks 20s 75 mg coated tablets
Mylan/Viatris (France)
Physiotens® 28's 0.4 mg coated tablets